• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Variation in Serum PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9), Cardiovascular Disease Risk, and an Investigation of Potential Unanticipated Effects of PCSK9 Inhibition.血清前蛋白转化酶枯草溶菌素9型（PCSK9）的变异、心血管疾病风险以及PCSK9抑制潜在意外效应的研究
Circ Genom Precis Med. 2019 Jan;12(1):e002335. doi: 10.1161/CIRCGEN.118.002335.
2
Genetic Assessment of Potential Long-Term On-Target Side Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibitors.PCSK9（前蛋白转化酶枯草溶菌素 9）抑制剂潜在长期靶标副作用的遗传评估。
Circ Genom Precis Med. 2019 Jan;12(1):e002196. doi: 10.1161/CIRCGEN.118.002196.
3
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.前蛋白转化酶枯草溶菌素/克新9型（PCSK9）抑制剂：当前观点与未来展望。
Nutr Metab Cardiovasc Dis. 2016 Oct;26(10):853-62. doi: 10.1016/j.numecd.2016.05.006. Epub 2016 May 30.
4
Efficacy and safety of proprotein convertase subtilisin/kexin 9 inhibitors in people with diabetes and dyslipidaemia.在患有糖尿病和血脂异常的人群中，丝氨酸蛋白酶 9 抑制剂的疗效和安全性。
Diabetes Obes Metab. 2019 Apr;21 Suppl 1:39-51. doi: 10.1111/dom.13636.
5
Lipid Lowering Therapy and Circulating PCSK9 Concentration.降脂治疗与循环 PCSK9 浓度。
J Atheroscler Thromb. 2017 Sep 1;24(9):895-907. doi: 10.5551/jat.RV17012. Epub 2017 Aug 14.
6
Cyclase-associated protein 1 is a binding partner of proprotein convertase subtilisin/kexin type-9 and is required for the degradation of low-density lipoprotein receptors by proprotein convertase subtilisin/kexin type-9.衔接蛋白 1 是蛋白水解酶原转化酶枯草溶菌素/柯萨奇蛋白酶 9 的结合伴侣，并且对于蛋白水解酶原转化酶枯草溶菌素/柯萨奇蛋白酶 9 降解低密度脂蛋白受体是必需的。
Eur Heart J. 2020 Jan 7;41(2):239-252. doi: 10.1093/eurheartj/ehz566.
7
Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes.载脂蛋白 B 代谢关键基因 PCSK9 和 HMGCR 变异与心血管疾病和糖尿病风险
N Engl J Med. 2016 Dec 1;375(22):2144-2153. doi: 10.1056/NEJMoa1604304.
8
Proprotein convertase subtilisin/kexin type 9-inhibition across different patient populations.前蛋白转化酶枯草溶菌素 9 抑制剂在不同患者人群中的应用。
Curr Opin Lipidol. 2024 Aug 1;35(4):179-186. doi: 10.1097/MOL.0000000000000935. Epub 2024 Mar 27.
9
PCSK9 Inhibitors and Cardiovascular Disease: Impact on Cardiovascular Outcomes.PCSK9 抑制剂与心血管疾病：对心血管结局的影响。
Curr Drug Discov Technol. 2020;17(2):138-146. doi: 10.2174/1570163816666181211112358.
10
Effects of PCSK9 Inhibitors on Other than Low-Density Lipoprotein Cholesterol Lipid Variables.前蛋白转化酶枯草溶菌素9（PCSK9）抑制剂对除低密度脂蛋白胆固醇之外的脂质变量的影响。
J Cardiovasc Pharmacol Ther. 2018 Jan;23(1):3-12. doi: 10.1177/1074248417724868. Epub 2017 Aug 22.

引用本文的文献

1
Causal relationships of familial hypercholesterolemia with the risk of multiple vitamin deficiencies: a Mendelian randomization study.家族性高胆固醇血症与多种维生素缺乏风险的因果关系：一项孟德尔随机化研究。
Front Endocrinol (Lausanne). 2024 Oct 22;15:1401260. doi: 10.3389/fendo.2024.1401260. eCollection 2024.
2
PCSK9 genetic variants and risk of vascular and non-vascular diseases in Chinese and UK populations.PCSK9 基因变异与中、英人群血管和非血管疾病风险的关系。
Eur J Prev Cardiol. 2024 Jun 3;31(8):1015-1025. doi: 10.1093/eurjpc/zwae009.
3
The HUNT study: A population-based cohort for genetic research.HUNT研究：一项基于人群的基因研究队列。
Cell Genom. 2022 Oct 12;2(10):100193. doi: 10.1016/j.xgen.2022.100193.
4
Cohort Profile Update: The HUNT Study, Norway.队列简介更新：挪威HUNT研究。
Int J Epidemiol. 2023 Feb 8;52(1):e80-e91. doi: 10.1093/ije/dyac095.
5
Genome-Wide Association of Proprotein Convertase Subtilisin/Kexin Type 9 Plasma Levels in the ELSA-Brasil Study.巴西成人健康纵向研究中前蛋白转化酶枯草杆菌蛋白酶/克新蛋白酶9型血浆水平的全基因组关联研究
Front Genet. 2021 Sep 29;12:728526. doi: 10.3389/fgene.2021.728526. eCollection 2021.

本文引用的文献

1
Circulating PCSK9 and Risk of Myocardial Infarction: The HUNT Study in Norway.循环中前蛋白转化酶枯草溶菌素9与心肌梗死风险：挪威的HUNT研究
JACC Basic Transl Sci. 2016 Nov 30;1(7):568-575. doi: 10.1016/j.jacbts.2016.06.007. eCollection 2016 Dec.
2
The MR-Base platform supports systematic causal inference across the human phenome.MR-Base 平台支持在人类表型全范围内进行系统因果推断。
Elife. 2018 May 30;7:e34408. doi: 10.7554/eLife.34408.
3
Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes.载脂蛋白 B 代谢关键基因 PCSK9 和 HMGCR 变异与心血管疾病和糖尿病风险
N Engl J Med. 2016 Dec 1;375(22):2144-2153. doi: 10.1056/NEJMoa1604304.
4
Meta-analysis of 65,734 individuals identifies TSPAN15 and SLC44A2 as two susceptibility loci for venous thromboembolism.对65734名个体进行的荟萃分析确定TSPAN15和SLC44A2为静脉血栓栓塞的两个易感基因座。
Am J Hum Genet. 2015 Apr 2;96(4):532-42. doi: 10.1016/j.ajhg.2015.01.019. Epub 2015 Mar 12.
5
The Swedish Twin Registry: establishment of a biobank and other recent developments.瑞典双胞胎登记处：生物样本库的建立及其他近期进展。
Twin Res Hum Genet. 2013 Feb;16(1):317-29. doi: 10.1017/thg.2012.104. Epub 2012 Nov 9.

Variation in Serum PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9), Cardiovascular Disease Risk, and an Investigation of Potential Unanticipated Effects of PCSK9 Inhibition.

作者信息

Brumpton Ben M, Fritsche Lars G, Zheng Jie, Nielsen Jonas Bille, Mannila Maria, Surakka Ida, Rasheed Humaira, Vie Gunnhild Åberge, Graham Sarah E, Gabrielsen Maiken Elvestad, Laugsand Lars Erik, Aukrust Pål, Vatten Lars Johan, Damås Jan Kristian, Ueland Thor, Janszky Imre, Zwart John-Anker, Van't Hooft Ferdinand M, Seidah Nabil Georges, Hveem Kristian, Willer Cristen, Smith George Davey, Åsvold Bjørn Olav

机构信息

Department of Public Health and Nursing, K.G. Jebsen Center for Genetic Epidemiology (B.M.B., L.G.F., H.R., G.Å.V., M.E.G., K.H., B.O.Å.), NTNU, Norwegian University of Science and Technology, Trondheim.

MRC Integrative Epidemiology Unit, University of Bristol, United Kingdom (B.M.B., J.Z., H.R., G.D.S.).

出版信息

Circ Genom Precis Med. 2019 Jan;12(1):e002335. doi: 10.1161/CIRCGEN.118.002335.

DOI:10.1161/CIRCGEN.118.002335
PMID:30645169
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6530796/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c40a/6530796/eafc6d4265bd/nihms-1512649-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c40a/6530796/eafc6d4265bd/nihms-1512649-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c40a/6530796/eafc6d4265bd/nihms-1512649-f0001.jpg